EX-10.1





 Exhibit 10.1 

AMENDMENT TO EMPLOYMENT AGREEMENT 

This Amendment to Employment Agreement (this “Amendment”) is entered into as of October 19, 2020 and effective as of
October 13, 2020, by and between Cogent Biosciences, Inc. (formerly known as Unum Therapeutics, Inc.), a Delaware corporation (the “Company”) and John L. Green (the “Executive”) 

WHEREAS, the Company and the Executive are parties to an Employment Agreement, dated as of July 6, 2020 (the “Employment
Agreement”); 
 WHEREAS, the Company and the Executive wish to amend certain provisions of the Employment Agreement; and 

WHEREAS, capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to them in the Employment
Agreement. 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by
the Executive and the Company, the parties agree as follows: 
 1. Section 2(a) of the Employment Agreement is hereby amended and restated
in its entirety as follows: 
 (a) Base Salary. Beginning October 13, 2020, the Executive’s base salary shall be $401,450.
The Executive’s base salary may be redetermined annually by the Board or the Compensation Committee of the Board (the “Compensation Committee”). The base salary in effect at any given time is referred to herein as “Base
Salary.” The Base Salary shall be payable in a manner that is consistent with the Company’s usual payroll practices for senior executives. 

2. Section 2(b) of the Employment Agreement is hereby amended and restated in its entirety as follows: 

(b) Incentive Compensation. During the Term, the Executive shall be eligible to receive cash incentive compensation as determined by
the Board or the Compensation Committee from time to time. The Executive’s initial target annual incentive compensation shall be 40% of his Base Salary. The actual amount of the Executive’s annual incentive compensation, if any, shall be
determined in the sole discretion of the Board or the Compensation Committee, subject to the terms of any applicable incentive compensation plan that may be in effect from time to time. Except as otherwise provided herein, as may be provided by the
Board or the Compensation Committee or as may otherwise be set forth in any applicable incentive compensation plan, to earn or receive any annual incentive compensation, the Executive must be employed by the Company on the day such incentive
compensation is paid. 
 3. All other provisions of the Employment Agreement, including without limitation those set forth in Sections 7 and
10 of the Employment Agreement, shall remain in full force and effect according to their respective terms, and nothing contained herein shall be deemed a waiver of any right or abrogation of any obligation otherwise existing under the Employment
Agreement except to the extent specifically provided for herein. 

  
 1 













 4. The validity, interpretation, construction and performance of this Amendment, and the
Employment Agreement, as amended herein, shall be governed in accordance with Sections 8 and 9 of the Employment Agreement. 
 5. This
Amendment may be executed in several counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instrument. 

[Remainder of page intentionally left blank.] 

  
 2 













 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first set
forth above. 
  

			
	COGENT BIOSCIENCES, INC.
		
	By:	 	 /s/ Erin Schellhammer

	Name:	 	Erin Schellhammer
	Title:	 	Chief People Officer


  

	
	EXECUTIVE
	
	 /s/ John L. Green

	John L. Green
	Chief Financial Officer